- Home
- MIRM vs WRD Comparison
MIRM vs WRD Comparison
Compare MIRM & WRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- WRD
- Stock Information
- Founded
- MIRM 2018
- WRD 2017
- Country
- MIRM United States
- WRD China
- Employees
- MIRM N/A
- WRD N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- WRD
- Sector
- MIRM Health Care
- WRD
- Exchange
- MIRM Nasdaq
- WRD NYSE
- Market Cap
- MIRM 2.5B
- WRD 2.8B
- IPO Year
- MIRM 2019
- WRD 2024
- Fundamental
- Price
- MIRM $48.39
- WRD $7.64
- Analyst Decision
- MIRM Strong Buy
- WRD Buy
- Analyst Count
- MIRM 9
- WRD 2
- Target Price
- MIRM $66.22
- WRD $22.00
- AVG Volume (30 Days)
- MIRM 463.0K
- WRD 9.9M
- Earning Date
- MIRM 08-06-2025
- WRD 08-25-2025
- Dividend Yield
- MIRM N/A
- WRD N/A
- EPS Growth
- MIRM N/A
- WRD N/A
- EPS
- MIRM N/A
- WRD N/A
- Revenue
- MIRM $379,251,000.00
- WRD $49,940,881.00
- Revenue This Year
- MIRM $35.83
- WRD N/A
- Revenue Next Year
- MIRM $16.83
- WRD $218.93
- P/E Ratio
- MIRM N/A
- WRD N/A
- Revenue Growth
- MIRM 69.31
- WRD N/A
- 52 Week Low
- MIRM $33.45
- WRD $6.03
- 52 Week High
- MIRM $54.23
- WRD $44.00
- Technical
- Relative Strength Index (RSI)
- MIRM 50.61
- WRD N/A
- Support Level
- MIRM $49.39
- WRD N/A
- Resistance Level
- MIRM $51.93
- WRD N/A
- Average True Range (ATR)
- MIRM 1.52
- WRD 0.00
- MACD
- MIRM -0.18
- WRD 0.00
- Stochastic Oscillator
- MIRM 14.49
- WRD 0.00
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About WRD WERIDE INC. SPON ADS EACH REP 3 CL A ORD SHS
WeRide Inc operates in the autonomous driving industry. The company has developed a universal autonomous driving technology platform that integrates full-stack software algorithms, modularized hardware solutions, and a cloud-based infrastructure platform. The company provides autonomous driving products and services from L2 to L4 vehicles. The products of the company includes Robotaxi, Robobus, Robovan, Robosweeper, and others. The company earns its revenue from the People's Republic of China.